Negotiators Prioritize Generic And Biosimilar Oncology Medicines Over Newer Drugs
UICC And WHO Will Bargain For Cheaper Cancer Drugs For LMICs
The Union for International Cancer Control and the World Health Organization are prioritizing off-patent drugs in their efforts to facilitate oncology medicine access in developing nations.
You may also be interested in...
The Medicines Patent Pool has struck a milestonedeal with new partner Novartis for nilotinib to treat chronic myeloid leukemia, representing the first MPP agreement in non-communicable diseases as well as the “first ever public health-oriented voluntary license agreement on a cancer medicine.”
The Union for International Cancer Control has established the Access to Oncology Medicines Coalition to facilitate access to cancer drugs in low and lower-middle-income countries.
The “Accord for a Healthier World” pledges to provide patent-protected medicines on a not-for-profit basis in 45 lower-income nations. Pfizer, which profited most from the COVID-19 pandemic, sees the pandemic experience as a way to advance health equity.